TEDDY 2018-11-21T11:00:06+00:00



Role of CVBF



The TEDDY Network of Excellence (NoE) arose from the Task-force in Europe for Drug Development for the Young, a consortium funded in 2005 as TEDDY project (LSHB-CT-2005-005216) within the Sixth Framework Programme of the European Commission with the aim to favour the integration of the paediatric pharmacological research activities, the implementation of adequate health policies and a social awareness on the importance of the paediatric medicines across Europe covering different specialty areas (haematology, oncology, infectious diseases, respiratory diseases, intensive care, pain, endocrinology, rare diseases, neonatology).

At the end of the 5-years funding period, the consortium was further renewed and now TEDDY is operating as an independent multidisciplinary, multinational network including 50 members in 20 EU and non EU-countries.

The main objective of TEDDY network is to promote research on medicinal products in children providing methodological expertise and implementing good practices, Standard Operating Procedures (SOPs) and tools to plan, design and perform clinical studies at national and international level. Moreover, by developing ad hoc informative and educational tools, TEDDY aims to increase awareness on the topics of paediatric research and to encourage the participation of children in all the relevant experimental procedures.

TEDDY is a category 1 network member of Enpr-EMA, the European Network of Paediatric Research at the European Medicines Agency, and collaborates with existing paediatric networks and research organisations with the goal to promote and foster scientific and technological excellence in the paediatric research in Europe.

All the activities and key decisions of the Network are coordinated by 3 bodies, the Network Scientific Committee (NSC), the Scientific Coordinating Committee (SCC) and the Strategic Planning Board (SPB).

The Network Scientific Committee (NSC) coordinates TEDDY’s scientific activities with the aim to share knowledge and experiences among Partners and to ensure that the relevant scientific objectives are met. It has decision-making power and consists of 73 members, one member for each Partner plus more than 20 experts directly appointed by the General Assembly (GA).

The NSC activities are coordinated by a Scientific Coordination Committee (SCC) that is in charge of developing new strategies, projects and studies. It includes six members: Annagrazia Altavilla (Espace Ethique Méditerranéen Aix-Marseille Université), Adriana Ceci (Fondazione per la Ricerca Farmacologica Gianni Benzi Onlus), Giovanni Migliaccio (Consorzio per Valutazioni Biologiche e Farmacologiche), Oscar Della Pasqua (University College London), Francesca Rocchi (Ospedale Pediatrico Bambino Gesù), Saskia de Wildt (Radboud University Nijmegen & Erasmus MC).

The Strategic Planning Board (SPB) is the Network’s advisory body, aimed at guarantee the consistency between the original aims of the TEDDY project funded within FP6 and the current topics arising in the paediatric research field. The SPB deal with establishing productive relationship with Institutions and stakeholders and ensures the adherence to the high quality standards of the Network. It includes six members: Carlo Giaquinto (Fondazione PENTA Onlus), Maria Mellado Peña (Hospital Universitario La Paz), Marek Migdal (Instytut Pomnik Centrum Zdrowia Dziecka), Miriam Sturkenboom (University Medical Center Utrecht), Mark Turner (University of Liverpool), Ian Wong (University College of London).


  • Assistance Publique – Hôpitaux de Paris, France;
  • Assiut university Faculty of Medicine, Egypt;
  • Azienda Ospedaliera Antonio Cardarelli, Naples, Italy;
  • Azienda Ospedaliera di Padova, Italy;
  • Azienda Ospedaliera Ospedali Riuniti Villa Sofia-Cervello, Palermo, Italy;
  • Azienda Ospedaliero Universitaria Consorziale Policlinico di Bari, Italy;
  • Azienda Ospedaliero-Universitaria di Modena, Italy;
  • Barts Health NHS Trust, London, United Kingdom;
  • Cairo University, Egypt;
  • Center for Strategic Research North-West as Coordinator of the Alliance for Translational Medicine, St. Petersburg, Russia;
  • Centre National de Greffe de Moelle Osseuse, Tunis, Tunisia;
  • Charité – Universitätsmedizin Berlin, Germany;
  • Childhood Cancer International, Nieuwegein, The Netherlands;
  • Consorzio per Valutazioni Biologiche e Farmacologiche, Bari, Italy (Coordinator);
  • Consorzio per Valutazioni Biologiche e Farmacologiche – Dege e shoqerise se huaj, Tirana,  Albania;
  • Erasmus MC Sophia Children’s Hospital, Rotterdam, The Netherlands;
  • Erasmus Universitair Medisch Centrum Rotterdam, The Netherlands;
  • Espace Ethique Méditerranéen CHU Marseille (AP-HM/Aix-Marseille Université), France;
  • Fondazione PENTA Onlus, Padua, Italy;
  • Fondazione per la Ricerca Farmacologica ‘Gianni Benzi’ Onlus, Bari, Italy;
  • Fundación para la Investigación del Hospital Universitario y Politécnico La Fe de la Comunidad Valenciana, Spain;
  • Fundación para la Investigación, Desenvolvemento e Innovación Ramón Domínguez, Santiago de Compostela, Spain;
  • Fundaciò Sant Joan de Déu, Barcelona, Spain;
  • Geniko Nosokomeio Paidon Athinon I Agia Sophia-Paidon Pentelis, Athens, Greece;
  • Gothia Forum Sahlgrenska University Hospital, Göteborg, Sweden;
  • Gruppo Italiano per gli Studi di Farmacoeconomia, Pavia,  Italy;
  • Hospital Clínico Universitario de Santiago de Compostela, Spain;
  • Hospital Universitario 12 de Octubre, Madrid, Spain;
  • Hospital Universitario La Paz, Madrid Spain;
  • Inserm SC10, Villejuif , France;
  • Institute of Physiology of ASCR, v.v.i., Praha, Czech Republic;
  • Instytut Pomnik – Centrum Zdrowia Dziecka, Warszawa, Poland;
  • Istituto Superiore di Sanità, Rome, Italy;
  • Medical and Public Health Services of the Cyprus Ministry of Health, Cyprus;
  • National and Kapodistrian University of Athens, Greece;
  • Ospedale Pediatrico Bambino Gesù, Rome, Italy;
  • PHARM – PHArmaceutical Research Management Srl, Lodi, Italy;
  • PharmaSich Plus, LLC, Kiev, Ukraine;
  • Phoenix Clinical Research, Beirut, Lebanon;
  • Romanian Angel Appeal Foundation, Bucharest, Romania;
  • Società Servizi Telematici Srl, Padua,  Italy;
  • Technion – Israel Institute of Technology, Haifa, Israel;
  • Università degli Studi “Gabriele D’Annunzio” Chieti Pescara, Italy;
  • Università degli Studi di Napoli Federico II, Dipartimento di Pediatria, Italy;
  • Universitätsklinikum Erlangen, Germany;
  • University College London, United Kingdom;
  • University Hospital Center “Mother Teresa”, Tirana, Albania;
  • University of Edinburgh, United Kingdom;
  • University of Honk Kong, China;
  • University of Liverpool, United Kingdom.